The Journal of Nuclear Medicine

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Retrieved on: 
Thursday, June 15, 2023
Research, Medical Devices, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, GE HealthCare, The Journal of Nuclear Medicine, Neoplasm, Molecular imaging, Clinical trial, RECIST, Cancer, GE, PET, Multimedia, Nuclear medicine, Immunotherapy, Journal, CD8, Patient, Physician, Diagnosis, Cardiology, Neurology, Safety, Medical imaging

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Key Points: 
  • The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.
  • The study will also then help identify early response to immunotherapies, using sequential whole-body imaging to monitor CD8 changes over time, enabling physicians to switch patients who are not responding to alternative treatment options sooner.
  • The clinical trial, initiated in the Netherlands, is studying the safety and tolerability of the 18F-labeled radiopharmaceutical in patients with solid tumor malignancies.
  • the effect of immunotherapies on a patient’s immune response to their cancer - could, potentially, enable them to better select patients to participate in clinical trials and bring new immunotherapies to market.

Prostate Cancer Nuclear Medicine Diagnostics Markets, 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 1, 2022
Oncology, Health, Consumer, Seniors, Radiology, Men, Pharmaceutical, Prostate cancer, COVID-19, Medicaid, PET, Cancer, Centers for Medicare & Medicaid Services, Nuclear medicine, SPECT, Skin cancer, CMS, Health, Diagnosis, Common, National coverage determination, Health insurance, Journal, Adoption, PCA, Center, Positron emission tomography, CAGR, American Pet Products Association, NCD, Growth, The Journal of Nuclear Medicine, Efficiency, Radiology, Medical imaging, Medicare

The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028.

Key Points: 
  • The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028.
  • Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.
  • Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET.
  • Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics.

White Plains Hospital Acquires PET/MRI—Only Hospital in All of New York Outside of NYC to Offer this Most Advanced Imaging Technology

Retrieved on: 
Tuesday, September 7, 2021
Medical Devices, Health, Hospitals, Other Health, Radiology, Biotechnology

White Plains Hospital's new PET/MRI scanner--groundbreaking radiology technology that provides the most comprehensive look at the human body for cancer detection and assessment of neurological conditions. (Photo: Business Wire)

Key Points: 
  • With only 115 PET/MRIs available worldwide, White Plains Hospital is the first and only healthcare facility in the Hudson Valley and Fairfield County to have this new technology.
  • The PET/MRI scanner is one of many advanced healthcare services offered at White Plains Hospitals new Center for Advanced Medicine & Surgery (CAMS).
  • To find out more about PET/MRI and the advanced imaging capabilities at White Plains Hospital, visit wphospital.org/diagnosticimaging .
  • White Plains Hospital performs lifesaving emergency and elective angioplasty in its Joan and Alan Herfort, MD, Cardiac Catheterization Laboratory and Marie Promuto Cardiac Catheterization Laboratory .

Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

Retrieved on: 
Thursday, August 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Survival, Prostate cancer, Toxicity, University, NOX, Lupinus, Neoplasm, MCRPC, Mouse, Drug development, Safety, Man, Inflammation, Septic shock, Nuclear medicine, NYR, University of Queensland, ASX, The Journal of Nuclear Medicine, Journal, Animal, Pharmaceutical industry

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer.

Key Points: 
  • Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer.
  • This result validates the survival benefit of the same combination seen in a recently completed Phase I/II trial of Veyonda in men with end-stage metastatic castrate-resistant prostate cancer (mCRPC).
  • A study in mice bearing human prostate cancer xenografts, and led by Professor Kristofer Thurecht, Ph.D., at The University of Queensland, confirmed a potent ability of Veyonda to enhance the cancer-killing effect of LuPSMA treatment.
  • The LuPIN study was a non-randomized study, so the question remained of how much the remarkable outcome of 19.7 months was due to the combination effect versus LuPSMA monotherapy alone, said Noxopharm CEO, Graham Kelly.

CereHealth Showcases "Going Against the Norm" During the Society of Nuclear Medicine and Molecular Imaging's Annual Meeting

Retrieved on: 
Thursday, July 9, 2020
Health sciences, Health, Medicinal radiochemistry, Radiology, Articles, Nuclear medicine, The Journal of Nuclear Medicine, Therapy, Medicine

The virtual conference, entitled "Diagnosis to Therapy: The Future of Image-Guided Patient Management," will be attended virtually by over 2,500 society members and insiders of the nuclear medicine and molecular imaging industry worldwide.

Key Points: 
  • The virtual conference, entitled "Diagnosis to Therapy: The Future of Image-Guided Patient Management," will be attended virtually by over 2,500 society members and insiders of the nuclear medicine and molecular imaging industry worldwide.
  • A recorded oral presentation of the collaboration between Ms. Quandt and coauthor, Dr. Cyrus Raji, MD, PhD, will be featured in the conference's online Science Pavilion1.
  • She will highlight how the population template was generated from over 2,000 heterogenous clinical scans and validated against a normative dataset of 90 controls.
  • Journal of Nuclear Medicine, 61 (Supplement 1), pp.76, 2020 ( link ).

ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine

Retrieved on: 
Tuesday, October 8, 2019
Academic journals, Periodicals, Publications, The Journal of Nuclear Medicine, Radiology, Acta Radiologica, American College of Radiology

LOS ANGELES, Oct. 8, 2019 /PRNewswire/ --ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM).

Key Points: 
  • LOS ANGELES, Oct. 8, 2019 /PRNewswire/ --ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM).
  • The data from the Phase I trial reported in the paper demonstrated 89Zr-Df-IAB22M2C was well tolerated with no immediate or delayedside effects observed.
  • In conclusion, the study found 89Zr- Df-IAB22M2C imaging to be safe and with favorable kinetics for early imaging.
  • Ian Wilson, CEO of ImaginAb, added: "We are delighted that this paper has been published in The Journal of Nuclear Medicine, a highly regarded publication in the field of imaging and radiology.